Last updated: September 8, 2026
Raxibacumab is a government-stockpiled anthrax monoclonal antibody with limited conventional market potential. FDA approved the drug in 2012 under the Animal Rule for treatment of inhalational anthrax, in combination with appropriate antibacterial drugs, and for post-exposure prophylaxis when alternative therapies are unavailable or inappropriate.[1] Its commercial economics depend primarily on U.S. government procurement, stockpile replenishment and national biodefense policy rather than hospital demand.
Public disclosures do not show a material recurring commercial revenue stream for raxibacumab. The product was developed and sponsored by Human Genome Sciences and GlaxoSmithKline under the brand ABthrax. Raxibacumab competes in a narrow biodefense category with obiltoxaximab, marketed as Anthim by Elusys and later associated with Emergent BioSolutions. The main financial risks are procurement timing, government budget changes, manufacturing continuity and the availability of competing anthrax countermeasures.
What is raxibacumab and how is it used?
Raxibacumab is a fully human IgG1 monoclonal antibody directed against the protective antigen component of Bacillus anthracis toxin. By binding protective antigen, it inhibits the cellular entry of anthrax toxin components.[1]
| Attribute |
Raxibacumab |
| Active ingredient |
Raxibacumab |
| Original brand |
ABthrax |
| Drug class |
Human monoclonal antibody |
| Target |
Bacillus anthracis protective antigen |
| FDA application |
Biologics License Application 125349 |
| Approval date |
December 14, 2012 |
| FDA pathway |
Animal Rule |
| Approved use |
Inhalational anthrax treatment and post-exposure prophylaxis |
| Administration |
Intravenous infusion |
| Standard adult dose |
40 mg/kg as a single dose |
| Pediatric dosing |
Weight-based dosing under the prescribing information |
| Companion therapy |
Appropriate antibacterial drugs for treatment |
| Primary buyer |
U.S. government and biodefense agencies |
The FDA approval did not rest on controlled human efficacy trials because inhalational anthrax is too rare and dangerous for conventional clinical efficacy studies. The regulatory package relied on animal efficacy data, pharmacokinetic bridging and human safety information.[1]
How large is the raxibacumab market?
The addressable commercial market is small and structurally concentrated. Raxibacumab is not a routine hospital product, an outpatient prescription drug or a broad infectious-disease therapy. Demand is created mainly by government stockpile requirements.
The principal market characteristics are:
- The U.S. government is the dominant potential customer.
- Orders are episodic rather than recurring.
- Revenue depends on contract awards, option exercises and stockpile rotation.
- Private-sector demand is negligible.
- International government demand is possible but not a reliable substitute for U.S. procurement.
The Strategic National Stockpile maintains medical countermeasures for chemical, biological, radiological and nuclear threats. Anthrax products can be procured through the Biomedical Advanced Research and Development Authority, the Administration for Strategic Preparedness and Response and related federal contracting channels.[2]
Raxibacumab therefore operates as a readiness product. Its value is linked to availability during a low-probability, high-consequence event rather than to the number of diagnosed patients in a normal year.
What is the financial trajectory for raxibacumab?
Public financial reporting does not provide a reliable standalone revenue series for raxibacumab. Government contracts have generally been reported at the corporate or portfolio level, while raxibacumab-related sales have not been disclosed as a major recurring revenue category in recent public filings.
Financial trajectory
| Period |
Commercial development |
Financial implication |
| 2008-2011 |
Federal development and procurement support for anthrax countermeasures |
Development economics depended on government funding and advance procurement |
| 2012 |
FDA approval of ABthrax |
Enabled stockpile sales but did not create a conventional commercial market |
| 2013-2016 |
Early post-approval government procurement and product positioning |
Revenue remained contract-driven |
| 2017 onward |
Narrow biodefense portfolio and competition from obiltoxaximab |
Product-level visibility declined; procurement became the primary value driver |
| 2020-2024 |
COVID-19 spending increased attention to biodefense but did not create broad raxibacumab demand |
No evidence of a durable commercial sales expansion |
| 2024 onward |
Core exclusivity periods have expired or are expiring, while stockpile demand remains the principal opportunity |
Manufacturing and procurement execution matter more than ordinary prescription growth |
The product’s financial profile is best described as lumpy government revenue with low unit volume and potentially high contract value per dose. That profile can generate attractive revenue during a procurement cycle, but it does not support predictable annual growth.
For a manufacturer, the economic case depends on:
- A federal purchase order large enough to justify dedicated production.
- Long-term supply or replenishment commitments.
- Shelf-life extension that reduces stockpile waste.
- Manufacturing capacity that can be maintained without excessive idle cost.
- Regulatory support for process changes and comparability.
- Continued federal prioritization of anthrax countermeasures.
The absence of transparent product-level revenue makes it inappropriate to estimate raxibacumab sales from total company revenue. Government contract announcements should be separated from recognized product revenue, because a contract ceiling may include options, services, replenishment, development work or multiple products.
When does raxibacumab lose exclusivity?
Raxibacumab had multiple forms of regulatory protection, but the practical effect of exclusivity is limited by the narrow market.
Regulatory exclusivity
The FDA approved raxibacumab in December 2012. The 12-year reference-product exclusivity period for a biologic approved under the Public Health Service Act would generally run to December 2024, subject to the statutory calculation and any applicable regulatory issues.[3]
Raxibacumab also received orphan-drug protection associated with anthrax treatment. Orphan exclusivity generally lasts seven years from approval, placing the relevant period around December 2019.[4]
| Protection |
Approximate end point |
Commercial significance |
| Orphan-drug exclusivity |
December 2019 |
Limited protection against the same approved orphan indication |
| Biologic reference-product exclusivity |
December 2024 |
Delayed submission of a biosimilar application under the 351(k) pathway |
| Patent protection |
Requires family-by-family verification |
No reliable commercial conclusion should be drawn from regulatory exclusivity alone |
Regulatory exclusivity does not prevent all competing products. Another sponsor could potentially develop a distinct anthrax monoclonal antibody, seek approval through a different pathway or compete for the same government contract.
What patents protect raxibacumab?
Raxibacumab is a biologic, so its competitive position is not captured by the small-molecule Orange Book model. Biologic patent information is handled through patent disclosures and the Purple Book framework rather than through ordinary Orange Book listing practice.[5]
The relevant intellectual-property categories include:
- Antibody composition claims.
- Binding-site or epitope claims.
- Nucleic-acid and host-cell claims.
- Cell-culture and purification methods.
- Formulation and stability claims.
- Methods of treating or preventing anthrax.
- Manufacturing and analytical methods.
No broad, current patent number or unexpired patent family should be treated as the definitive barrier to competition without a live review of U.S. Patent and Trademark Office records, assignment records and litigation history. FDA approval alone does not establish that a product has an enforceable patent barrier.
The commercial barrier may instead be operational. A competing sponsor would need to demonstrate consistent antibody manufacturing, establish potency assays, validate impurity controls, maintain cold-chain distribution and generate sufficient animal and human safety data for the intended pathway.
Is raxibacumab listed in the Orange Book or Purple Book?
Raxibacumab is not a conventional small-molecule drug with an Orange Book patent-and-exclusivity profile. Its biologic status makes the Purple Book and the FDA’s reference-product framework more relevant.[5]
The key distinction is:
| Issue |
Raxibacumab implication |
| Orange Book |
Not the primary source for biologic reference-product protection |
| Purple Book |
Relevant to biologic reference-product and biosimilar status |
| Paragraph IV certification |
Applies to listed small-molecule patents, not as the primary route for a 351(k) biosimilar |
| Biosimilar litigation |
Governed by the Biologics Price Competition and Innovation Act patent process |
| Patent disclosure |
Depends on sponsor and regulatory disclosure practices |
No widely reported Paragraph IV challenge or major biosimilar litigation involving raxibacumab has emerged in the public record cited here.
What biosimilar risk does raxibacumab face?
Near-term biosimilar risk has historically been low because the market is small, the disease indication is highly specialized and government procurement is uncertain. The end of reference-product exclusivity increases legal eligibility for a biosimilar application, but it does not guarantee commercial entry.
A biosimilar developer would face several barriers:
- Limited annual demand.
- Uncertain stockpile procurement schedules.
- High cost of biologic analytical and nonclinical development.
- Need for validated assays for protective-antigen binding and neutralization.
- Potentially complex comparability work if the reference manufacturing process changed.
- Dependence on federal contracting rather than ordinary payer substitution.
- Competition from alternative anthrax antibodies and antibiotics.
A biosimilar could still be commercially rational if the federal government sought multiple suppliers for resilience, lower pricing or surge capacity. That scenario would depend on procurement policy rather than automatic substitution at pharmacies.
Which companies compete with raxibacumab?
The most relevant direct competitor is obiltoxaximab, an anthrax monoclonal antibody approved by the FDA in 2016 under the brand Anthim.[6]
| Product |
Active ingredient |
Sponsor or commercial association |
Regulatory position |
| ABthrax |
Raxibacumab |
Developed by Human Genome Sciences and GlaxoSmithKline |
FDA-approved anthrax monoclonal antibody |
| Anthim |
Obiltoxaximab |
Elusys; later associated with Emergent BioSolutions |
FDA-approved anthrax monoclonal antibody |
| Anthrax antibiotics |
Various antibacterials |
Multiple manufacturers |
Used as primary or companion therapy |
| Vaccines |
Anthrax vaccine products |
Government and commercial suppliers |
Prevention and post-exposure countermeasure role |
Raxibacumab and obiltoxaximab compete for the same strategic objective: inclusion in federal anthrax preparedness programs. The competition is therefore based on procurement price, supply reliability, shelf life, manufacturing readiness, regulatory support and portfolio integration.
What patent litigation or settlement agreements affect raxibacumab?
No major public patent litigation or settlement agreement is identified in the cited record as a material current driver of raxibacumab’s market position. The absence of visible litigation is consistent with the product’s small market and limited number of potential entrants.
The more important legal issues are likely to involve:
- Government contract terms.
- Procurement protests.
- Product liability and readiness obligations.
- Manufacturing changes.
- Patent scope around antibody compositions and production.
- Biosimilar patent exchanges if a future 351(k) applicant emerges.
A lack of litigation does not establish freedom to operate. It indicates only that litigation has not been a prominent public market event.
What regulatory and manufacturing barriers protect raxibacumab?
Raxibacumab’s strongest barriers are regulatory and operational rather than demand-side barriers.
Regulatory barriers
The Animal Rule requires a sponsor to establish that the animal models predict human benefit and that the product’s pharmacology and manufacturing are sufficiently controlled.[1] A follow-on product would need a credible scientific bridge to the approved reference product.
Manufacturing barriers
Production requires:
- Mammalian-cell biologic manufacturing.
- Controlled upstream and downstream processing.
- Viral safety and impurity controls.
- Potency testing against protective antigen.
- Stability data supporting stockpile storage.
- Validated fill-finish and intravenous presentation.
- Continued FDA oversight of process changes.
For a stockpile product, shelf life is a financial variable. A longer approved shelf life reduces replacement frequency and can improve the government’s cost per usable dose. A shorter shelf life increases replenishment needs but also raises manufacturer obligations and inventory risk.
How does raxibacumab compare with obiltoxaximab?
Raxibacumab and obiltoxaximab have similar strategic roles but different commercial histories.
| Factor |
Raxibacumab |
Obiltoxaximab |
| FDA approval |
2012 |
2016 |
| Target |
Protective antigen |
Protective antigen |
| Use |
Treatment and post-exposure prophylaxis |
Treatment and post-exposure prophylaxis |
| Evidence basis |
Animal Rule |
Animal Rule |
| Market |
Government biodefense stockpile |
Government biodefense stockpile |
| Primary risk |
Limited procurement and uncertain commercial continuity |
Procurement concentration and portfolio competition |
| Substitution |
Not automatic |
Not automatic |
| Commercial growth driver |
Federal stockpile contracts |
Federal stockpile contracts |
Neither product has a normal prescription-growth trajectory. The competitive outcome depends on federal purchasing strategy, available supply and the government’s preference for single-source or multi-source readiness.
What generic launch scenarios exist for raxibacumab?
A conventional generic launch is unlikely because raxibacumab is a biologic. The relevant scenarios are:
- A biosimilar sponsor submits a 351(k) application after reference-product exclusivity.
- A distinct monoclonal antibody competes through a separate biologics application.
- A government procurement program selects a different anthrax antibody without formal biosimilar substitution.
- The federal government maintains multiple suppliers for resilience, preserving room for both products.
- No entrant pursues approval because the market cannot support development costs.
The highest-probability commercial pressure is not pharmacy-level substitution. It is government-led price competition during contract renewals.
What is the investment outlook for raxibacumab?
Raxibacumab is unlikely to be a standalone growth asset. Its value is better assessed as part of a biodefense platform or government-contractor portfolio.
Positive factors
- FDA approval and established regulatory history.
- Strategic relevance to national biodefense.
- Potential for large periodic procurement orders.
- High barriers to rapid biologic manufacturing entry.
- Possible demand for supplier diversification.
Negative factors
- No broad private market.
- Low visibility into product-level revenue.
- Dependence on federal budgets and contracting cycles.
- Competition from obiltoxaximab and antibiotics.
- Inventory, expiration and shelf-life exposure.
- Limited value from ordinary physician prescribing.
- Potential post-2024 biosimilar or alternative-biologic pressure.
The financial trajectory is therefore best characterized as mature, procurement-dependent and event-driven. Revenue upside exists through stockpile replenishment, but base-case expectations should not assume steady year-over-year growth.
Key Takeaways
- Raxibacumab is an FDA-approved anthrax monoclonal antibody sold originally as ABthrax.
- Its principal market is U.S. government biodefense procurement, not routine clinical use.
- Public disclosures do not establish a material recurring commercial revenue stream.
- FDA approval in 2012 implies that the standard 12-year biologic reference-product exclusivity period reached approximately December 2024.
- Orphan-drug exclusivity likely ended around December 2019.
- The product does not have a conventional Orange Book generic-entry profile.
- Biosimilar risk is legally more relevant after 2024, but market economics remain a major deterrent.
- Obiltoxaximab is the principal direct product competitor.
- Government procurement timing, shelf life and manufacturing continuity are more important than prescription volume.
- Raxibacumab is more valuable as a strategic biodefense capability than as a conventional commercial pharmaceutical asset.
FAQs
Is raxibacumab still commercially available?
Raxibacumab’s practical availability is tied to government biodefense procurement and sponsor supply arrangements. It is not a routine retail or hospital pharmacy product.
Is raxibacumab the same drug as Anthim?
No. Raxibacumab was associated with ABthrax. Anthim is the brand associated with obiltoxaximab, a different anthrax monoclonal antibody.
Can a generic company copy raxibacumab?
A conventional generic pathway is not applicable. A potential entrant would generally need to pursue a biologic or biosimilar regulatory strategy.
Does raxibacumab generate normal pharmaceutical sales?
No public evidence supports treating raxibacumab as a normal recurring prescription product. Its economics are driven by federal stockpile contracts and replenishment cycles.
What would most increase raxibacumab revenue?
A new Strategic National Stockpile purchase, expanded federal preparedness requirements, supplier-diversification policy or a major anthrax event would have the greatest potential to increase demand.
References
- U.S. Food and Drug Administration. (2012). ABthrax (raxibacumab) injection prescribing information. https://www.accessdata.fda.gov
- Administration for Strategic Preparedness and Response. (n.d.). Strategic National Stockpile. U.S. Department of Health and Human Services. https://aspr.hhs.gov/SNS
- U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2016). Anthim (obiltoxaximab) prescribing information. https://www.accessdata.fda.gov
